Zacks Research Has Positive Forecast for COO Q3 Earnings

The Cooper Companies, Inc. (NASDAQ:COO) – Stock analysts at Zacks Research raised their Q3 2027 earnings estimates for shares of Cooper Companies in a note issued to investors on Thursday, March 26th. Zacks Research analyst Team now anticipates that the medical device company will post earnings per share of $1.25 for the quarter, up from their previous forecast of $1.24. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings data on Thursday, March 5th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.03 by $0.07. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. Cooper Companies had a net margin of 9.67% and a return on equity of 10.34%. Cooper Companies’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.92 earnings per share. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS.

A number of other analysts have also recently issued reports on the company. Wells Fargo & Company upped their target price on Cooper Companies from $72.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, December 5th. Weiss Ratings upgraded Cooper Companies from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, January 12th. Mizuho set a $100.00 price objective on Cooper Companies and gave the company an “outperform” rating in a report on Friday, December 5th. The Goldman Sachs Group restated a “sell” rating and set a $73.00 target price on shares of Cooper Companies in a research report on Friday, January 9th. Finally, Wall Street Zen raised shares of Cooper Companies from a “hold” rating to a “buy” rating in a report on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Cooper Companies has a consensus rating of “Moderate Buy” and an average price target of $90.79.

Cooper Companies Price Performance

COO opened at $69.77 on Monday. Cooper Companies has a one year low of $61.78 and a one year high of $89.83. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.79 and a current ratio of 1.34. The stock has a market capitalization of $13.61 billion, a P/E ratio of 34.54, a price-to-earnings-growth ratio of 1.80 and a beta of 1.02. The business’s 50-day simple moving average is $78.82 and its 200-day simple moving average is $76.22.

Institutional Trading of Cooper Companies

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rockefeller Capital Management L.P. increased its holdings in shares of Cooper Companies by 156.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 18,855 shares of the medical device company’s stock valued at $1,545,000 after purchasing an additional 11,503 shares during the period. Larry Mathis Financial Planning LLC purchased a new stake in shares of Cooper Companies during the fourth quarter worth approximately $489,000. River Road Asset Management LLC lifted its holdings in shares of Cooper Companies by 1.0% during the fourth quarter. River Road Asset Management LLC now owns 1,582,867 shares of the medical device company’s stock worth $129,732,000 after purchasing an additional 16,103 shares during the period. Kera Capital Partners Inc. acquired a new stake in shares of Cooper Companies during the fourth quarter worth $216,000. Finally, Axxcess Wealth Management LLC grew its position in Cooper Companies by 37.1% in the 4th quarter. Axxcess Wealth Management LLC now owns 9,980 shares of the medical device company’s stock valued at $818,000 after buying an additional 2,698 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Zacks Research raised several quarterly and full‑year EPS forecasts for Cooper (FY2026–FY2028 and multiple quarters), signaling improved analyst expectations for margin and earnings momentum — a catalyst that can support the stock over time. Zacks boosts COO estimates (MarketBeat summary)
• Neutral Sentiment: A Zacks feature highlights Cooper’s premium contact‑lens momentum and margin gains as reasons to consider adding the stock, which underpins a constructive medium‑term view but notes mixed near‑term signals. Reasons to Add Cooper Companies Stock to Your Portfolio Now
• Negative Sentiment: The same analyst coverage warns of Asia market softness and broader geopolitical risks that could blunt top‑line growth for Cooper’s international lens business — a near‑term headwind that likely contributed to today’s selling. Risks: Asia weakness & geopolitical concerns (Zacks)

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.